




In the format provided by the authors and unedited.


# Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Jun Wang<sup>1,5</sup>, Jingwei Sun<sup>1,5</sup>, Linda N. Liu<sup>2</sup>, Dallas B. Flies<sup>2</sup>, Xinxin Nie<sup>1</sup>, Maria Toki<sup>3</sup>, Jianping Zhang<sup>1</sup>, Chang Song<sup>2</sup>, Melissa Zarr<sup>2</sup>, Xu Zhou <sup>1</sup>, Xue Han<sup>1</sup>, Kristina A. Archer<sup>2</sup>, Thomas O'Neill<sup>2</sup>, Roy S. Herbst<sup>4</sup>, Agedi N. Boto<sup>1,3</sup>, Miguel F. Sanmamed<sup>1</sup>, Solomon Langermann<sup>2</sup>, David L. Rimm <sup>3,4</sup> and Lieping Chen <sup>1,4\*</sup>

---

<sup>1</sup>Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. <sup>2</sup>NextCure Inc, Beltsville, MD, USA. <sup>3</sup>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. <sup>4</sup>Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA. <sup>5</sup>These authors contributed equally: Jun Wang, Jingwei Sun \*e-mail: [lieping.chen@yale.edu](mailto:lieping.chen@yale.edu)

**Supplementary Table 1**



**Supplementary Table 2**

<b>Yale NSCLC cohort</b>			
		Number (n=241)	Percentage (%)
<b>Age</b>	<70	122	50.6
	≥70	96	39.8
	Unknown	23	9.5
<b>Sex</b>	Female	123	51.0
	Male	97	40.2
	Unknown	21	8.7
<b>Smoking history</b>	Never smoker	32	13.3
	Former/Current smoker	174	72.2
	Unknown	35	14.5
<b>Stage</b>	I/II	175	72.6
	III/IV	37	15.4
	Unknown	29	12.0
<b>Histology</b>	ADC	121	50.2
	SCC	59	24.5
	Other	38	15.8
	Unknown	23	9.5

**Supplementary Table 1. Homology of human Siglec-15 to the B7 family proteins.** An alignment of human Siglec-15 to human B7 family proteins was conducted using the Protein Blast program (NCBI). Data are displayed as the identity (x -axis) and the identity plus similarity (y -axis) of the extracellular domains of these molecules.

**Supplementary Table 2: Clinicopathological characteristics of the patients from the Yale NSCLC cohort.**